70
Participants
Start Date
April 2, 2019
Primary Completion Date
July 29, 2022
Study Completion Date
July 29, 2022
Cisplatin
Cisplatin was administered intravenously at a dose of 75 milligrams per meter square (mg/m\^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Carboplatin
Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Pemetrexed
Pemetrexed was administered intravenously at a dose of 500 mg/ m\^2 over 10 minutes every 21 days.
Nab-paclitaxel
Nab-paclitaxel was administered intravenously at as dose of 100 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).
Gemcitabine
Gemcitabine was administered intravenously at a dose of 1250 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
Docetaxel
Docetaxel was administered intravenously at a dose of 75 mg/m\^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
M7824
M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
Carboplatin
Carboplatin was administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Carboplatin
Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
Bintrafusp alfa
M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
Paclitaxel
Paclitaxel was administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
RCCA MD LLC - Bethesda, Bethesda
University of Maryland - DUPLICATE/Pediatric Surgery, Baltimore
Hematology - Oncology Associates of Treasure Coast - Hematology-Oncology Associates of Treasure Coast, Port Saint Lucie
Baptist Health Lexington Oncology Associates, Lexington
Henry Ford Health System, Detroit
California Cancer Associates for Research & Excellence, Inc., San Marcos
Compassionate Care Research Group Inc - Edinger Medical Group, Inc., Fountain Valley
Vanderbilt University Medical Center, Nashville
Universitair Ziekenhuis Brussel - Geriatrie, Brussels
UZ Antwerpen, Edegem
Universitair Ziekenhuis Gent - Medical Oncology, Ghent
CHU Sart Tilman, Liège
AZ Sint-Maarten, Mechelen
Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Maison du Ha, Bordeaux
Centre Georges François Leclerc - Unité de Phase I, Dijon
Hôpital de la Timone# - CPCEM CIC - Bat F 1er étage, Marseille
ICO - Site René Gauducheau, Nantes
Centre Antoine Lacassagne, Nice
CHU Poitiers - Hôpital la Milétrie - service d'oncologie médicale, Poitiers
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY